Odanacatib

Odanacatib

Systematic (IUPAC) name
N-(1-cyanocyclopropyl)-4-fluoro-N^2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)biphenyl-4-yl]ethyl}-L-leucinamide
Clinical data
Routes of administration	oral
Identifiers
CAS Number	603139-19-1
ATC code	none
PubChem	CID 10152654
IUPHAR/BPS	6478
ChemSpider	8328162
UNII	N673F6W2VH
ChEMBL	CHEMBL481611
Synonyms	(2S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-{[(1S)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide
Chemical data
Formula	C25H27F4N3O3S
Molar mass	525.56 g/mol
SMILES CC(C)(CC(C(=O)NC1(CC1)C#N)NC(C2=CC=C(C=C2)C3=CC=C(C=C3)S(=O)(=O)C)C(F)(F)F)F
InChI InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1 Key:FWIVDMJALNEADT-SFTDATJTSA-N
(what is this?)  (verify)

Odanacatib (pINN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis.^[1] It is an inhibitor of cathepsin K,^[2] an enzyme involved in bone resorption.

It is being developed by Merck & Co.. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. Merck announced in 2014 that it would apply for regulatory approval in 2015,^[3] but as of early 2016 there was no report of any application. In 2014 Cowen and Co predicted odanacatib will generate a billion USD per year in sales by 2020.^[4]

This drug was developed at Merck Frosst in Montreal.

References

1. Le Gall, C. L.; Bonnelye, E.; Clézardin, P. (2008). "Cathepsin K inhibitors as treatment of bone metastasis". Current Opinion in Supportive and Palliative Care 2 (3): 218–22. doi:10.1097/SPC.0b013e32830baea9. PMID 18685424.
2. Gauthier JY, Chauret N, Cromlish W, et al. (February 2008). "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K". Bioorg. Med. Chem. Lett. 18 (3): 923–8. doi:10.1016/j.bmcl.2007.12.047. PMID 18226527.
3. http://www.reuters.com/article/2014/09/15/us-merck-osteoporosis-idUSKBN0HA1Y820140915
4. "Merck to seek approval of osteoporosis drug, cites safety risks". Reuters. 2014-05-06.